OR WAIT null SECS
December 15, 2025
Article
FDA approves lerodalcibep, a groundbreaking PCSK9 inhibitor, offering a monthly injection for LDL cholesterol reduction in patients with HoFH.
December 05, 2025
This FDA News Month in Review provides a round-up of regulatory decisions from November 2025.
December 04, 2025
Catch up with major FDA decisions, critical conference news, and more.
November 29, 2025
Video
O’Donoghue discusses the results of this analysis of the FOURIER trial, highlighting that no limit was found for lowered LDL-C improving MACE risk.
November 27, 2025
O’Donoghue discusses the results of the recent OCEAN(a)-DOSE trial and addresses the implications for Lp(a)-lowering therapies moving forward.
November 26, 2025
Explore the critical role of nutrition and pharmacologic therapies in managing hypertriglyceridemia and preventing pancreatitis effectively.
Explore how the latest FDA approvals impact the management of FCS.
Panelists break down the potential role of plozasiran in FCS based on the PALISADE trial.
Understanding severe hypertriglyceridemia is crucial for preventing pancreatitis and managing triglyceride levels effectively.
